ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
AbCellera Biologics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.93+0.13 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$6.34 (+113.4%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
AbCellera Biologics Inc. grew revenue 101.3% to $66.17M over the twelve months to Jun 30, 2026. Free cash flow was -$119.67M.
Revenue
$66.17M
+101.3% vs. a year earlier
Operating income
-$225.16M
TTM Q2 2026
Free cash flow
-$119.67M
TTM Q2 2026
EPS, diluted
-$0.54
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.65B
- P/E ratio
- –
- Price to sales
- 55.09
- Price to book
- 4.07
- Dividend yield
- –
- Free cash flow yield
- -3.28%
Fundamentals
- Revenue
- $66.17M
- Net income
- -$164.66M
- EPS, diluted
- -$0.54
- Free cash flow
- -$119.67M
- Book value per share
- $2.93
- Diluted shares
- 306M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$66.17M+101.3% YoY
Operating income
-$225.16M
Net income
-$164.66M
EPS, diluted
-$0.54
Free cash flow
-$119.67M
Reported periodTrailing twelve months